Alpha-1 antitrypsin deficiency

Alpha-1 antitrypsin deficiency is a genetic disorder that increases susceptibility to early-onset emphysema and, in some cases, liver disease. The condition results from mutations in the SERPINA1 gene, which lead to low circulating levels of alpha-1 antitrypsin, a protein responsible for protecting lung tissue from enzymatic damage. Without adequate protection, lung tissue undergoes accelerated destruction, especially in individuals who smoke or experience frequent respiratory infections. Early recognition is critical, as many patients remain undiagnosed until significant lung function is lost. Diagnosis relies on blood testing, genetic confirmation, and clinical evaluation. Current management strategies emphasize lifestyle modification, particularly smoking cessation, alongside standard COPD treatments such as bronchodilators, inhaled corticosteroids, and pulmonary rehabilitation. For eligible patients, augmentation therapy with intravenous alpha-1 antitrypsin provides disease-specific benefit by restoring protective protein levels, slowing progression of emphysema. Emerging research into gene therapy and recombinant protein products is exploring curative potential. Beyond pharmacological approaches, vaccinations, nutritional support, and proactive infection management are vital in preserving long-term lung health. Multidisciplinary care—including pulmonologists, hepatologists, and genetic counselors—ensures comprehensive management across organ systems. With increasing awareness and improved therapeutic strategies, alpha-1 antitrypsin deficiency is shifting from an underrecognized cause of lung disease to a condition with expanding opportunities for effective intervention.